Moderna Company Insiders

MRNA Stock  USD 33.64  0.64  1.87%   
About 94 percent of Moderna's insiders are activelly selling. The analysis of the overall insider sentiment regarding Moderna suggests that a very large number of insiders are panicking. Moderna employs about 5.8 K people. The company is managed by 25 executives with a total tenure of roughly 13534 years, averaging almost 541.0 years of service per executive, having 232.0 employees per reported executive.

Insider Sentiment 6

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-04-10Ro KhannaDisposed @ 24.5
2025-04-08Robert Bresnahan, Jr.Disposed @ 24.64
2025-02-25Robert Bresnahan, Jr.Acquired @ 33.22
2025-01-15Julie JohnsonDisposed @ 34.77
2024-12-09Shannon Thyme KlingerDisposed 529 @ 44.68View
2024-12-03Stephen HogeDisposed 314 @ 43.3View
2024-11-29Stephen HogeDisposed 291 @ 42.79View
2024-10-07James M MockDisposed 715 @ 60.12View
2024-09-03Shannon Thyme KlingerDisposed 114 @ 76.99View
2024-08-29Stephen HogeDisposed 300 @ 78.03View
2024-08-28James M MockDisposed 1321 @ 79.39View
2024-08-12Stephen HogeDisposed 254 @ 84.1View
2024-07-31Noubar AfeyanDisposed 15000 @ 119.96View
2024-07-24Noubar AfeyanDisposed 15000 @ 117.8View
2024-07-17Noubar AfeyanDisposed 15000 @ 122.84View
2024-07-15Stephen HogeDisposed 15000 @ 121.12View
Monitoring Moderna's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Moderna's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Moderna. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Moderna's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

Moderna's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Moderna's future performance. Based on our forecasts, it is anticipated that Moderna will maintain a workforce of about 5800 employees by August 2025.
 
Covid

Moderna's latest congressional trading

Congressional trading in companies like Moderna, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Moderna by those in governmental positions are based on the same information available to the general public.
2025-05-08Representative Rob BresnahanAcquired Under $15KVerify
2025-03-28Representative Rob BresnahanAcquired Under $15KVerify

Moderna Management Team Effectiveness

The company has return on total asset (ROA) of (0.1584) % which means that it has lost $0.1584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2934) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.24. The current year's Return On Capital Employed is expected to grow to -0.31. The current year's Net Tangible Assets is expected to grow to about 23.1 B, whereas Total Assets are forecasted to decline to about 9.6 B.
The current year's Net Income Applicable To Common Shares is expected to grow to about 10.1 B, whereas Common Stock Shares Outstanding is forecasted to decline to about 354.1 M.

Moderna Workforce Comparison

Moderna is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 67,932. Moderna holds roughly 5,800 in number of employees claiming about 9% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.06) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (9.72) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $9.72.

Moderna Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Moderna insiders, such as employees or executives, is commonly permitted as long as it does not rely on Moderna's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Moderna insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-06-01
1.0
25
25
 173,590 
 15,302 
2025-03-01
0.871
27
31
 1,172,370 
 43,742 
2024-12-01
0.8947
17
19
 403,615 
 15,645 
2024-09-01
0.375
15
40
 21,214 
 90,761 
2024-06-01
0.2131
26
122
 111,919 
 478,912 
2024-03-01
0.5789
22
38
 518,103 
 144,124 
2023-12-01
0.2414
7
29
 11,906 
 112,710 
2023-09-01
0.1077
7
65
 23,990 
 224,045 
2023-06-01
0.2133
32
150
 566,151 
 2,115,307 
2023-03-01
0.157
27
172
 779,321 
 2,186,271 
2022-12-01
0.1467
33
225
 655,834 
 2,364,736 
2022-09-01
0.1164
27
232
 509,562 
 2,451,426 
2022-06-01
0.2133
48
225
 410,136 
 1,801,403 
2022-03-01
0.2407
39
162
 465,934 
 918,687 
2021-12-01
0.289
63
218
 401,667 
 1,389,250 
2021-09-01
0.2478
56
226
 365,000 
 1,572,003 
2021-06-01
0.3213
107
333
 616,404 
 1,461,570 
2021-03-01
0.1615
73
452
 749,131 
 11,566,604 
2020-12-01
0.1495
45
301
 524,296 
 1,575,981 
2020-09-01
0.203
67
330
 1,268,963 
 23,944,558 
2020-06-01
0.1613
45
279
 2,430,487 
 18,379,608 
2020-03-01
0.1491
17
114
 1,734,649 
 1,095,566 
2019-12-01
0.2353
8
34
 1,217,171 
 11,306,769 
2019-09-01
0.3333
1
3
 100,000 
 205,000 
2018-12-01
0.2716
22
81
 61,587,803 
 48,565,415 
2018-06-01
5.5
11
2
 1,243,077 
 0.00 
2014-03-01
1.0
3
3
 1,493,606 
 108,041 
2011-09-01
7.0
7
1
 982,500 
 40,200 
2011-03-01
0.038
3
79
 126,253 
 404,005 
2010-09-01
0.5
3
6
 35,938 
 237,850 
2009-03-01
4.0
4
1
 1,091,275 
 800,000 
2008-09-01
1.0
5
5
 10,000 
 1,190 

Moderna Notable Stakeholders

A Moderna stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moderna often face trade-offs trying to please all of them. Moderna's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moderna's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stphane BancelCEO DirectorProfile
Melanie MBAChief OfficerProfile
Stephane BancelCEO DirectorProfile
Dave JohnsonChief OfficerProfile
Lavina CFASenior RelationsProfile
Noubar AfeyanIndependent CoFounderProfile
Allison MDSenior DevelopmentProfile
Colleen HusseySenior CommunicationsProfile
Patrick BergstedtSenior VaccinesProfile
Lori PantherInfectious DevelopmentProfile
Jerh CollinsChief OfficerProfile
Juan AndresPres ExpansionProfile
Charbel MPHSenior ScienceProfile
Shannon KlingerChief SecretaryProfile
Brad MillerChief OfficerProfile
James MockChief OfficerProfile
John ReyndersChief OfficerProfile
Ruchi JainPrincipal ScientistProfile
Melissa MooreChief BoardProfile
Stephen MDPresidentProfile
Shannon JDChief SecretaryProfile
Tracey FranklinChief OfficerProfile
Michelle HallPrincipal ChemistryProfile
Phil WhiteVice ManagementProfile
MD FAAPSenior DevelopmentProfile

About Moderna Management Performance

The success or failure of an entity such as Moderna often depends on how effective the management is. Moderna management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moderna management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moderna management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.25)(0.24)
Return On Capital Employed(0.33)(0.31)
Return On Assets(0.25)(0.24)
Return On Equity(0.33)(0.31)
Please note, the presentation of Moderna's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moderna's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Moderna's management manipulating its earnings.

Moderna Workforce Analysis

Traditionally, organizations such as Moderna use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moderna within its industry.

Moderna Manpower Efficiency

Return on Moderna Manpower

Revenue Per Employee557.9K
Revenue Per Executive129.4M
Net Loss Per Employee614K
Net Loss Per Executive142.4M
Working Capital Per Employee1M
Working Capital Per Executive235.7M

Complementary Tools for Moderna Stock analysis

When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals